Atara Biotherapeutics Inc. (ATRA) 63.79 $ATRA
Nasdaq stocks posting largest percentage increases
AP - 52 mins ago
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
AMSC: 10.40 (+1.20), ATRA: 63.79 (+7.64), VASC: 33.30 (+4.06), PKT: 11.42 (+1.91), ASML: 107.81 (+10.06), DWCH: 7.59 (+0.77), MIFI: 6.51 (+0.60), SURG: 5.11 (+0.49)
EBV-CTL Clinical Trial Data Presented by Atara Biotherapeutics' Collaborating Investigators at a Plenary Session at the American Association for Cancer Research Annual Meeting 2015
GlobeNewswire - Mon Apr 20, 5:30AM CDT
Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that its collaborating investigators at Memorial Sloan Kettering Cancer Center (MSK) presented data on its investigational cytotoxic T lymphocytes activated against Epstein-Barr Virus (EBV-CTL) at a Clinical Trials Plenary Session at the 2015 American Association for Cancer Research Annual Meeting (AACR). Clinical data from two clinical studies evaluating the safety and efficacy of EBV-CTL in the treatment of patients with EBV-associated lymphoproliferative disease (EBV-LPD) after allogeneic hematopoietic cell transplantation (HCT) was presented. Under Atara's exclusive option agreement with MSK, Atara has the right to license the exclusive, worldwide rights to three clinical stage T-cell programs, including EBV-CTL. EBV-LPD is a serious malignancy with an unmet medical need that occurs after HCT and in other patients with immune deficiencies. The U.S. Food and Drug Administration (FDA) recently granted breakthrough therapy designation for EBV-CTL based on the data from the two studies.
ATRA: 63.79 (+7.64)
Atara Biotherapeutics' Collaborating Investigators' Abstract on T-Cell Therapy for EBV Lymphoma to be Presented at a Clinical Trials Plenary Session at the American Association for Cancer Research Annual Meeting 2015 is Now Available
GlobeNewswire - Sun Apr 19, 7:30AM CDT
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), today announced that the abstract on cytotoxic T lymphocytes activated against Epstein-Barr Virus (EBV-CTL) that will be presented by its collaborating investigators at Memorial Sloan Kettering Cancer Center (MSK) at a Clinical Trials Plenary Session at the American Association for Cancer Research Annual Meeting (AACR) 2015 is now available. Clinical data on both the safety and efficacy of EBV-CTL in the treatment of patients with rituximab-refractory, EBV-associated lymphoproliferative disease (EBV-LPD) after allogeneic hematopoietic cell transplantation (HCT) will be presented. EBV-LPD is a serious malignancy with an unmet medical need that occurs after HCT and in other patients with immune deficiencies. The U.S. Food and Drug Administration (FDA) recently granted breakthrough therapy designation for EBV-CTL based on the data from the two studies. The AACR annual meeting is being held in Philadelphia, Pennsylvania from April 18th to April 22nd, 2015.
ATRA: 63.79 (+7.64)
The Top 5 Best IPO Performers in the Last Year
at The Street - Thu Apr 16, 2:56PM CDT
These are the top five best IPO performers in the last 12 months.
RDUS: 41.90 (-0.48), KITE: 57.56 (-1.43), CYBR: 65.53 (-0.84), ONCE: 64.79 (-0.25), ATRA: 63.79 (+7.64)
Mr. Klarman bullish on Atara Bio
Seeking Alpha - at Seeking Alpha - Thu Apr 16, 12:56PM CDT
ATRA: 63.79 (+7.64)
Baupost Ups Stake In Atara Biotherapeutics To 19.5%
ValueWalk - Seeking Alpha - Wed Apr 15, 10:32AM CDT
By Marie Cabural Seth Klarman’s Baupost Group increased its stake in Atara Biotherapeutics (NASDAQ: ATRA ) based on its latest 13G filing with the Securities and Exchange Commission (SEC). Based on the filing, Baupost Group...
ATRA: 63.79 (+7.64)
Atara Biotherapeutics, Inc. to Present at the 2015 Jefferies Immuno-Oncology Summit
GlobeNewswire - Mon Apr 13, 5:34AM CDT
Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that Isaac Ciechanover, M.D., the company's Chief Executive Officer, will present at the 2015 Jefferies Immuno-Oncology Summit on Wednesday, April 15, 2015 at 11:00 am EDT in Boston.
ATRA: 63.79 (+7.64)
Atara Biotherapeutics, Inc. to Present at the Needham Healthcare Conference
GlobeNewswire - Thu Apr 09, 5:30AM CDT
Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that Gad Soffer, the company's Chief Operating Officer, will present at the 2015 Needham Healthcare Conference on Tuesday, April 14, 2015 at 5:00 pm EDT in New York City.
ATRA: 63.79 (+7.64)
Week Ahead: Is GoDaddy The Master Of Its Domains? Up To 4 IPOs This Week
Renaissance Capital IPO Research - Seeking Alpha - Mon Mar 30, 6:26AM CDT
The IPO market should end the first quarter with a bang as GoDaddy (Pending: GDDY ) goes public during the shortened holiday week. GoDaddy to go public GoDaddy aims to raise $396 million at a market cap of $3 billion, or an enterprise value of...
WOWO: 8.41 (-0.88), KRNT: 14.99 (unch), VIRT: 21.81 (-0.54), TANH: 11.82 (+0.40), PRTY: 20.65 (-0.22), VRAY: (), VLRX: (), ATRA: 63.79 (+7.64), FGEN: 26.46 (-1.37), GDDY: 24.77 (-0.01)
Atara Biotherapeutics, Inc. Appoints Eric Dobmeier, Chief Operating Officer of Seattle Genetics, Inc., to Its Board of Directors
GlobeNewswire - Fri Mar 27, 5:30AM CDT
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing innovative therapies for patients with debilitating diseases, today announced that Eric Dobmeier has joined its Board of Directors.
SGEN: 36.92 (-0.32), ATRA: 63.79 (+7.64), STML: 16.51 (+0.13)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Mar 25, 11:45AM CDT
TANH: 11.82 (+0.40), CCSC: 5.36 (-0.04), STMP: 67.03 (-1.07), HGSH: 3.10 (-0.06), FSNN: 4.38 (+0.12), ATRA: 63.79 (+7.64), KRFT: 88.25 (-0.22), LPTN: 2.26 (unch), IIJI: 8.62 (-0.04), KFX: 11.02 (-0.01), ESPR: 100.53 (-2.60), FCSC: 4.01 (+0.01), ORMP: 7.25 (-0.10), AFMD: 7.94 (+0.11), SEED: 1.66 (+0.05), CALA: 12.93 (-1.06), LIME: 2.85 (-0.12), VBLT: 4.37 (-0.08), APOL: 17.64 (+0.11), REPH: 10.71 (-0.78)
Atara Biotherapeutics' Collaborating Investigators to Present Clinical Data on T-Cell Therapy for EBV Lymphoma at a Clinical Trials Plenary Session at the American Association for Cancer Research Annual Meeting 2015
GlobeNewswire - Thu Mar 19, 5:30AM CDT
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), today announced that its collaborating investigators at Memorial Sloan Kettering Cancer Center (MSK) will present clinical data from two studies of cytotoxic T lymphocytes activated against Epstein-Barr Virus (EBV-CTL) at a Clinical Trials Plenary Session at the American Association for Cancer Research Annual Meeting (AACR) 2015. Clinical data on both the safety and efficacy of EBV-CTL in the treatment of patients with rituximab-refractory, EBV-associated lymphoproliferative disease (EBV-LPD) after allogeneic hematopoietic cell transplantation (HCT) will be presented. EBV-LPD is a serious malignancy with an unmet medical need that occurs after HCT and in other patients with immune deficiencies. The U.S. Food and Drug Administration (FDA) recently granted breakthrough therapy designation for EBV-CTL based on the data from the two studies. The AACR annual meeting will be held in Philadelphia, Pennsylvania April 18th-22nd, 2015.
ATRA: 63.79 (+7.64)
FDA Designates New Treatment that Destroys EBV Expressing Cells as 'Breakthrough'; The Center for the Biology of Chronic Disease (CBCD) Reviews a Report
PRWeb - Thu Mar 12, 11:01PM CDT
"Infected with the Epstein Barr Virus (EBV)? The Center for the Biology of Chronic Disease (CBCD), which tested the formula of Novirin in two post-marketing clinical studies, recommends taking this natural antiviral supplement." - Greg Bennett, CBCD
ATRA: 63.79 (+7.64)
Nasdaq stocks posting largest percentage increases
AP - 52 mins ago
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
AMSC: 10.40 (+1.20), ATRA: 63.79 (+7.64), VASC: 33.30 (+4.06), PKT: 11.42 (+1.91), ASML: 107.81 (+10.06), DWCH: 7.59 (+0.77), MIFI: 6.51 (+0.60), SURG: 5.11 (+0.49)
EBV-CTL Clinical Trial Data Presented by Atara Biotherapeutics' Collaborating Investigators at a Plenary Session at the American Association for Cancer Research Annual Meeting 2015
GlobeNewswire - Mon Apr 20, 5:30AM CDT
Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that its collaborating investigators at Memorial Sloan Kettering Cancer Center (MSK) presented data on its investigational cytotoxic T lymphocytes activated against Epstein-Barr Virus (EBV-CTL) at a Clinical Trials Plenary Session at the 2015 American Association for Cancer Research Annual Meeting (AACR). Clinical data from two clinical studies evaluating the safety and efficacy of EBV-CTL in the treatment of patients with EBV-associated lymphoproliferative disease (EBV-LPD) after allogeneic hematopoietic cell transplantation (HCT) was presented. Under Atara's exclusive option agreement with MSK, Atara has the right to license the exclusive, worldwide rights to three clinical stage T-cell programs, including EBV-CTL. EBV-LPD is a serious malignancy with an unmet medical need that occurs after HCT and in other patients with immune deficiencies. The U.S. Food and Drug Administration (FDA) recently granted breakthrough therapy designation for EBV-CTL based on the data from the two studies.
ATRA: 63.79 (+7.64)
Atara Biotherapeutics' Collaborating Investigators' Abstract on T-Cell Therapy for EBV Lymphoma to be Presented at a Clinical Trials Plenary Session at the American Association for Cancer Research Annual Meeting 2015 is Now Available
GlobeNewswire - Sun Apr 19, 7:30AM CDT
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), today announced that the abstract on cytotoxic T lymphocytes activated against Epstein-Barr Virus (EBV-CTL) that will be presented by its collaborating investigators at Memorial Sloan Kettering Cancer Center (MSK) at a Clinical Trials Plenary Session at the American Association for Cancer Research Annual Meeting (AACR) 2015 is now available. Clinical data on both the safety and efficacy of EBV-CTL in the treatment of patients with rituximab-refractory, EBV-associated lymphoproliferative disease (EBV-LPD) after allogeneic hematopoietic cell transplantation (HCT) will be presented. EBV-LPD is a serious malignancy with an unmet medical need that occurs after HCT and in other patients with immune deficiencies. The U.S. Food and Drug Administration (FDA) recently granted breakthrough therapy designation for EBV-CTL based on the data from the two studies. The AACR annual meeting is being held in Philadelphia, Pennsylvania from April 18th to April 22nd, 2015.
ATRA: 63.79 (+7.64)
The Top 5 Best IPO Performers in the Last Year
at The Street - Thu Apr 16, 2:56PM CDT
These are the top five best IPO performers in the last 12 months.
RDUS: 41.90 (-0.48), KITE: 57.56 (-1.43), CYBR: 65.53 (-0.84), ONCE: 64.79 (-0.25), ATRA: 63.79 (+7.64)
Mr. Klarman bullish on Atara Bio
Seeking Alpha - at Seeking Alpha - Thu Apr 16, 12:56PM CDT
ATRA: 63.79 (+7.64)
Baupost Ups Stake In Atara Biotherapeutics To 19.5%
ValueWalk - Seeking Alpha - Wed Apr 15, 10:32AM CDT
By Marie Cabural Seth Klarman’s Baupost Group increased its stake in Atara Biotherapeutics (NASDAQ: ATRA ) based on its latest 13G filing with the Securities and Exchange Commission (SEC). Based on the filing, Baupost Group...
ATRA: 63.79 (+7.64)
Atara Biotherapeutics, Inc. to Present at the 2015 Jefferies Immuno-Oncology Summit
GlobeNewswire - Mon Apr 13, 5:34AM CDT
Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that Isaac Ciechanover, M.D., the company's Chief Executive Officer, will present at the 2015 Jefferies Immuno-Oncology Summit on Wednesday, April 15, 2015 at 11:00 am EDT in Boston.
ATRA: 63.79 (+7.64)
Atara Biotherapeutics, Inc. to Present at the Needham Healthcare Conference
GlobeNewswire - Thu Apr 09, 5:30AM CDT
Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that Gad Soffer, the company's Chief Operating Officer, will present at the 2015 Needham Healthcare Conference on Tuesday, April 14, 2015 at 5:00 pm EDT in New York City.
ATRA: 63.79 (+7.64)
Week Ahead: Is GoDaddy The Master Of Its Domains? Up To 4 IPOs This Week
Renaissance Capital IPO Research - Seeking Alpha - Mon Mar 30, 6:26AM CDT
The IPO market should end the first quarter with a bang as GoDaddy (Pending: GDDY ) goes public during the shortened holiday week. GoDaddy to go public GoDaddy aims to raise $396 million at a market cap of $3 billion, or an enterprise value of...
WOWO: 8.41 (-0.88), KRNT: 14.99 (unch), VIRT: 21.81 (-0.54), TANH: 11.82 (+0.40), PRTY: 20.65 (-0.22), VRAY: (), VLRX: (), ATRA: 63.79 (+7.64), FGEN: 26.46 (-1.37), GDDY: 24.77 (-0.01)
Atara Biotherapeutics, Inc. Appoints Eric Dobmeier, Chief Operating Officer of Seattle Genetics, Inc., to Its Board of Directors
GlobeNewswire - Fri Mar 27, 5:30AM CDT
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing innovative therapies for patients with debilitating diseases, today announced that Eric Dobmeier has joined its Board of Directors.
SGEN: 36.92 (-0.32), ATRA: 63.79 (+7.64), STML: 16.51 (+0.13)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Mar 25, 11:45AM CDT
TANH: 11.82 (+0.40), CCSC: 5.36 (-0.04), STMP: 67.03 (-1.07), HGSH: 3.10 (-0.06), FSNN: 4.38 (+0.12), ATRA: 63.79 (+7.64), KRFT: 88.25 (-0.22), LPTN: 2.26 (unch), IIJI: 8.62 (-0.04), KFX: 11.02 (-0.01), ESPR: 100.53 (-2.60), FCSC: 4.01 (+0.01), ORMP: 7.25 (-0.10), AFMD: 7.94 (+0.11), SEED: 1.66 (+0.05), CALA: 12.93 (-1.06), LIME: 2.85 (-0.12), VBLT: 4.37 (-0.08), APOL: 17.64 (+0.11), REPH: 10.71 (-0.78)
Atara Biotherapeutics' Collaborating Investigators to Present Clinical Data on T-Cell Therapy for EBV Lymphoma at a Clinical Trials Plenary Session at the American Association for Cancer Research Annual Meeting 2015
GlobeNewswire - Thu Mar 19, 5:30AM CDT
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), today announced that its collaborating investigators at Memorial Sloan Kettering Cancer Center (MSK) will present clinical data from two studies of cytotoxic T lymphocytes activated against Epstein-Barr Virus (EBV-CTL) at a Clinical Trials Plenary Session at the American Association for Cancer Research Annual Meeting (AACR) 2015. Clinical data on both the safety and efficacy of EBV-CTL in the treatment of patients with rituximab-refractory, EBV-associated lymphoproliferative disease (EBV-LPD) after allogeneic hematopoietic cell transplantation (HCT) will be presented. EBV-LPD is a serious malignancy with an unmet medical need that occurs after HCT and in other patients with immune deficiencies. The U.S. Food and Drug Administration (FDA) recently granted breakthrough therapy designation for EBV-CTL based on the data from the two studies. The AACR annual meeting will be held in Philadelphia, Pennsylvania April 18th-22nd, 2015.
ATRA: 63.79 (+7.64)
FDA Designates New Treatment that Destroys EBV Expressing Cells as 'Breakthrough'; The Center for the Biology of Chronic Disease (CBCD) Reviews a Report
PRWeb - Thu Mar 12, 11:01PM CDT
"Infected with the Epstein Barr Virus (EBV)? The Center for the Biology of Chronic Disease (CBCD), which tested the formula of Novirin in two post-marketing clinical studies, recommends taking this natural antiviral supplement." - Greg Bennett, CBCD
ATRA: 63.79 (+7.64)
